Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 7
1985 2
1986 5
1987 5
1988 2
1989 2
1990 1
1991 3
1992 9
1993 8
1994 5
1995 5
1996 1
1997 5
1998 4
1999 8
2000 8
2001 10
2002 8
2003 12
2004 25
2005 50
2006 49
2007 45
2008 36
2009 54
2010 81
2011 97
2012 83
2013 79
2014 102
2015 109
2016 124
2017 119
2018 134
2019 134
2020 118
2021 136
2022 145
2023 139
2024 142
2025 178
2026 106

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,136 results

Results by year

Filters applied: . Clear all
Page 1
Rifaximin treatment in hepatic encephalopathy.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Bass NM, et al. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893. N Engl J Med. 2010. PMID: 20335583 Free article. Clinical Trial.
CONCLUSIONS: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo. Rifaximin treatment also significantly reduced the risk of hospitalization involving hepatic encephalopathy. ...
CONCLUSIONS: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than d …
Rifaximin (Xifaxan) for Irritable Bowel Syndrome.
Karuppiah S, Pomianowski K. Karuppiah S, et al. Am Fam Physician. 2017 Feb 15;95(4):258-259. Am Fam Physician. 2017. PMID: 28290635 Free article. Review. No abstract available.
Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat.
Li H, Xiang Y, Zhu Z, Wang W, Jiang Z, Zhao M, Cheng S, Pan F, Liu D, Ho RCM, Ho CSH. Li H, et al. J Neuroinflammation. 2021 Nov 4;18(1):254. doi: 10.1186/s12974-021-02303-y. J Neuroinflammation. 2021. PMID: 34736493 Free PMC article.
Rifaximin increased the relative abundance of Ruminococcaceae and Lachnospiraceae, which were significantly positively correlated with the high level of butyrate in the brain. Rifaximin increased the content of anti-inflammatory factors released by microglia, and pr …
Rifaximin increased the relative abundance of Ruminococcaceae and Lachnospiraceae, which were significantly positively correlated wit …
Review of rifaximin as treatment for SIBO and IBS.
Pimentel M. Pimentel M. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175. Expert Opin Investig Drugs. 2009. PMID: 19243285 Review.
BACKGROUND: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. ...OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: Review of rifaximin clinical trials. RESULTS/ …
BACKGROUND: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resis …
Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, Bajaj JS. Sanyal AJ, et al. Hepatol Commun. 2024 May 10;8(6):e0436. doi: 10.1097/HC9.0000000000000436. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727685 Free PMC article. Clinical Trial.
BACKGROUND: The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes. METHODS: Pooled post hoc subgroup analysis of ad …
BACKGROUND: The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who …
Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
Fu J, Gao Y, Shi L. Fu J, et al. PLoS One. 2022 Apr 26;17(4):e0267647. doi: 10.1371/journal.pone.0267647. eCollection 2022. PLoS One. 2022. PMID: 35471992 Free PMC article.
Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive. ...Moreover, the use of r …
Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of …
Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis.
Wang J, Zhang L, Hou X. Wang J, et al. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1385-1399. doi: 10.1080/17474124.2021.2005579. Epub 2021 Nov 26. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34767484
OBJECTIVES: Over the past decades, rifaximin has been used to treat with small intestinal bacterial overgrowth (SIBO), however, the true efficacy remains unknown. ...Subgroup analysis and meta-regression indicated a dose-dependent eradication rate of rifaximin for S …
OBJECTIVES: Over the past decades, rifaximin has been used to treat with small intestinal bacterial overgrowth (SIBO), however, the t …
Rifaximin (Xifaxan) for traveler's diarrhea.
Keenum AJ, Stockton MD. Keenum AJ, et al. Am Fam Physician. 2005 Dec 15;72(12):2525-6. Am Fam Physician. 2005. PMID: 16370411 Free article. No abstract available.
Rifaximin-alpha reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, Galleron N, Huang X, Gencer S, Coen M, Tranah TH, Wendon JA, Bruce KD, Le Chatelier E, Ehrlich SD, Edwards LA, Shoaie S, Shawcross DL. Patel VC, et al. J Hepatol. 2022 Feb;76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. Epub 2021 Sep 24. J Hepatol. 2022. PMID: 34571050 Free article. Clinical Trial.
RESULTS: Patients were well-matched: median MELD (11 rifaximin-alpha vs. 10 placebo). Rifaximin-alpha did not lead to a 50% reduction in spontaneous neutrophil OB at 30 days compared to baseline (p = 0.48). ...Those on rifaximin-alpha were less likely to deve …
RESULTS: Patients were well-matched: median MELD (11 rifaximin-alpha vs. 10 placebo). Rifaximin-alpha did not lead to a 50% re …
2,136 results